DRUG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Bright Minds Biosciences Inc (DRUG) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 to invest. The company's financial performance is poor, with significant losses and no revenue growth. While technical indicators show some bullish signs, the lack of positive news, weak financials, and absence of strong trading signals suggest holding off on purchasing this stock for now.
The MACD is above 0 and positively contracting, indicating a potential bullish trend. RSI is neutral at 53.282, suggesting no clear overbought or oversold condition. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot level of 83.248, with resistance at 89.661 and support at 76.834.
Analysts have recently maintained an Outperform or Buy rating with high price targets, citing strong trial data for BMB-101 and its potential in treating absence seizures and other conditions.
The company's financial performance is extremely poor, with a significant drop in net income (-15349.58% YoY) and EPS (-9800.00% YoY). There is no recent news or significant trading trends from hedge funds, insiders, or Congress. The stock also experienced a 5% drop in the regular market session and a 2% pre-market decline.
In Q1 2026, revenue remained at 0 with no growth. Net income dropped significantly to -$7,565,318 (-15349.58% YoY), and EPS fell to -0.97 (-9800.00% YoY). Gross margin remained at 0 with no improvement.
Analysts have maintained positive ratings with high price targets (e.g., $126-$147) due to promising trial data for BMB-101. However, they emphasize the need for further safety evaluations and data from pivotal trials.
